MLTX - MoonLake Immunotherapeutics

NYSE * Healthcare * Biotechnology

$16.33

$-0.43 (-2.57%)

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

MLTX Key Statistics

Market Cap

$1.16B

0

P/B Ratio

4.00

EPS

$-3.33

Employees

100

How MLTX Compares to Peers

MLTX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

#6

of 6

CompanyP/EGrowthCompare
MLTXN/A0%-
AMGN25.60%vs AMGN
GILD19.30%vs GILD
VRTX31.10%vs VRTX
REGN17.60%vs REGN
BIIB15.10%vs BIIB

MoonLake Immunotherapeutics Company Information

Headquarters
Dorfstrasse 29, Zug, Switzerland, 6300, undefined
Website
www.moonlaketx.com
Sector
Healthcare
Industry
Biotechnology
Data Updated:
Ready to invest in MLTX?

Commission-free trading available. Affiliate links.

MLTX Lician Score

5% confidence
4.0/10
Neutral

MLTX has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates MLTXacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

MLTX Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

35810Value5.0Growth2.0Quality5.0Momentum5.0Safety5.04.4/10
5.0

Value

2.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for MLTX